GeoVax Labs, Inc.

GOVX | $1.54 5.48% 5.19% 22K

(0.0% 1d) (-27.4% 1m) (122.6% 1y) (0.0% 2d) (-4.6% 3d) (-14.6% 7d) (-44.15% volume)
Earnings Calendar: 2023-11-08
Market Cap: $ 3,554,796
http://www.geovax.com
Sec Filling | Patents | 6 employees

(US) GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and cancer using its novel vaccine platform. It focuses on human immunodeficiency virus, zika virus, hemorrhagic fever viruses, and malaria. The company was founded by Harriet Latham Robinson and Donald G. Hildebrand on September 9, 2006 and is headquartered in Smyrna, GA.

vaccine cancer immunotherapy infectious disease smallpox

add to watch list Paper trade email alert is off

Press-releases

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
Published: 2024-03-28 (Crawled : 13:00) - globenewswire.com
GOVX | $1.54 5.48% 5.19% 22K

Health Technology

| -23.16% | O: 4.21% H: 1.01% C: 1.01%
cm04 covid-19 vaccine congress world

GeoVax to Present at the 36th Annual Roth Conference
Published: 2024-03-12 (Crawled : 13:00) - globenewswire.com
GOVX | $1.54 5.48% 5.19% 22K

Health Technology

| -31.78% | O: 0.0% H: 4.21% C: -3.27%
conference

GeoVax to Present at the 2024 BIO CEO & Investor Conference
Published: 2024-02-19 (Crawled : 14:00) - globenewswire.com
GOVX | $1.54 5.48% 5.19% 22K

Health Technology

| Email alert Add to watchlist
ceo conference

GeoVax Announces Multiple Patent Issuances and Allowances
Published: 2024-02-13 (Crawled : 14:00) - globenewswire.com
GOVX | $1.54 5.48% 5.19% 22K

Health Technology

| -44.7% | O: 2.65% H: 0.0% C: -6.27%
patent

GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
GOVX | $1.54 5.48% 5.19% 22K

Health Technology

| -42.29% | O: 2.77% H: 2.69% C: 1.92%
cm04 covid-19 vaccine universal geo-cm04s1 positive trial

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
Published: 2024-01-29 (Crawled : 14:00) - globenewswire.com
GOVX | $1.54 5.48% 5.19% 22K

Health Technology

| 414.99% | O: 5.82% H: 0.0% C: -13.3%
nasdaq

GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
Published: 2024-01-08 (Crawled : 14:00) - globenewswire.com
GOVX | $1.54 5.48% 5.19% 22K

Health Technology

| 295.02% | O: 0.11% H: 4.05% C: 0.0%
medical

GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
Published: 2024-01-04 (Crawled : 00:00) - biospace.com/
GOVX | $1.54 5.48% 5.19% 22K

Health Technology

| 290.06% | O: 4.19% H: 0.0% C: -6.41%
gedeptin cancer trial advanced

GeoVax Announces Issuance of Malaria Vaccine Patent
Published: 2024-01-03 (Crawled : 14:00) - globenewswire.com
GOVX | $1.54 5.48% 5.19% 22K

Health Technology

| 294.59% | O: 2.7% H: 5.26% C: -1.5%
patent vaccine malaria

Novanta completes acquisition of Motion Solutions – Financial Post
Published: 2024-01-02 (Crawled : 22:00) - spacfeed.com
GOVX | $1.54 5.48% 5.19% 22K

Health Technology